Leerink Partnrs Lowers Earnings Estimates for Belite Bio

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of Belite Bio in a report released on Monday, July 7th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.46) per share for the quarter, down from their prior forecast of ($0.35). The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Belite Bio's Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $7.05 EPS.

BLTE has been the topic of a number of other reports. Benchmark reissued a "buy" rating and issued a $80.00 price target on shares of Belite Bio in a report on Wednesday, March 26th. Wall Street Zen cut shares of Belite Bio from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating on shares of Belite Bio in a research note on Thursday, May 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Belite Bio in a research report on Thursday, July 3rd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $96.67.

Belite Bio Price Performance

NASDAQ BLTE traded down $2.13 during trading on Thursday, hitting $62.03. 39,840 shares of the company's stock traded hands, compared to its average volume of 45,912. The business has a 50 day moving average of $61.70 and a 200-day moving average of $60.47. Belite Bio has a 12-month low of $43.70 and a 12-month high of $86.53.

Hedge Funds Weigh In On Belite Bio

Several institutional investors have recently modified their holdings of the company. Alyeska Investment Group L.P. bought a new position in shares of Belite Bio during the first quarter valued at about $5,538,000. GAMMA Investing LLC grew its stake in Belite Bio by 43.3% in the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock worth $122,000 after purchasing an additional 559 shares during the period. Bank of America Corp DE grew its position in shares of Belite Bio by 36.4% in the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock worth $1,157,000 after buying an additional 4,891 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Belite Bio in the 4th quarter worth about $155,000. Finally, XTX Topco Ltd lifted its position in Belite Bio by 30.9% during the 4th quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock valued at $446,000 after acquiring an additional 1,668 shares during the period. 0.53% of the stock is currently owned by institutional investors.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.